Pharming (PHAR) Research & Development (2020 - 2026)
Pharming (PHAR) posted Research & Development of -$25.6 million for Q1 2026, down 79616722.43% on a QoQ basis from -$32.1 in Q4 2025, and down 20.88% year-over-year from -$32.3 million in Q1 2025.
Pharming (PHAR) Research & Development (2020 - 2026) Analysis & Trends
Pharming's Research & Development history runs 7 years deep, the most recent figure standing at -$25.6 million for Q1 2026.
- Quarterly Research & Development fell 20.88% year-over-year to -$25.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$70.4 million (up 51.25% YoY) and the FY2025 annual result came in at $100.4 million, up 20.78% from the prior year.
- Research & Development was -$25.6 million for Q1 2026 at Pharming, down from -$32.1 in the prior quarter.
- Across five years, Research & Development topped out at -$20.7 in Q3 2024 and bottomed at -$83.1 million in Q4 2024.
- A 5-year average of -$24.7 million and a median of -$20.8 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development tumbled 145108102.44% — and 2025, when it surged 100.0%.
- Pharming's Research & Development stood at -$52.5 million in 2022, then surged by 100.0% to -$57.3 in 2023, then tumbled by 145108102.44% to -$83.1 million in 2024, then jumped by 100.0% to -$32.1 in 2025, then plunged by 79616722.43% to -$25.6 million in 2026.
- Business Quant data shows PHAR's Research & Development at -$25.6 million in Q1 2026, -$32.1 in Q4 2025, and -$23.4 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Pharming | 9.02 Bn | 8.96 Bn | 65.80 Mn | -25.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.56 Mn |
| Dec 31, 2025 | -32.10 |
| Sep 30, 2025 | -23.40 |
| Jun 30, 2025 | -44.84 Mn |
| Mar 31, 2025 | -21.14 Mn |
| Dec 31, 2024 | -83.15 Mn |
| Sep 30, 2024 | -20.70 |
| Jun 30, 2024 | -40.12 Mn |
| Mar 31, 2024 | -18.52 Mn |
| Dec 31, 2023 | -57.30 |
| Sep 30, 2023 | -20.75 Mn |
| Jun 30, 2023 | -36.53 Mn |
| Mar 31, 2023 | -15.62 Mn |
| Dec 31, 2022 | -52.50 Mn |
| Sep 30, 2022 | -12.30 Mn |
| Dec 31, 2021 | 35.81 Mn |
| Sep 30, 2021 | -13.32 Mn |
| Dec 31, 2020 | 28.35 Mn |
| Sep 30, 2020 | -9.13 Mn |